Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-321 (ripasudil) after descemetorhexis in Fuchs endothelial corneal dystrophy
2021-006456-14Phase 3Active
- Sponsor
- Kowa Research Institute, Inc.
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fuchs endothelial dystrophy (FED) comparing ripasudil with placebo (2 arms). Primary endpoint: Time to at least 40 ETDRS letter improvement in BCVA during the first 12 weeks after descemetorhexis. Started Jan 2023; status: active.
02
Drugs
ripasudil
03
Conditions
Fuchs endothelial dystrophy (FED)
Beyond the preview
Go deeper on 2021-006456-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006456-14.